The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Regulatory News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,742.00
Bid: 1,739.00
Ask: 1,742.00
Change: 0.00 (0.00%)
Spread: 3.00 (0.173%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,742.00
JMAT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Capital Markets Day Statement

21 Sep 2017 07:00

RNS Number : 3636R
Johnson Matthey PLC
21 September 2017
 

Johnson Matthey Capital Markets Day Statement

 

Today, Johnson Matthey will hold a capital markets day in which it will outline its strategy for growth and value creation, at a group level and across its sectors. This growth is underpinned by its leading positions in high margin, technology driven growth markets. The company expects to deliver sustained growth in Clean Air, break out growth in Battery Materials and Health, and above market growth in Efficient Natural Resources. In the medium term, this will generate attractive returns:

· Expanding group ROIC to 20%

· Delivering mid to high single digit EPS CAGR

· And continuing a progressive dividend policy

 

Overall our Clean Air business will deliver growth in the next ten years. It is expected to achieve strong single digit sales growth in the next two to three years from share gains already achieved in Europe light duty and from upcoming tighter legislation. In subsequent years, sales growth is expected to moderate as expansion in Asia, together with maintaining JM's strong position in heavy duty in North America, is partially offset by the move away from light duty diesel engines in Europe and by the increasing penetration globally of battery electric light duty vehicles.

The strategy for Efficient Natural Resources outlines how JM's technology leadership in the sector can deliver above market sales growth and improving operating margins from a focus on efficiency.

The programme of increased investment in the Health sector, which began in 2014, continues to build a deeper, broader pipeline of new products based on JM's expertise in active pharmaceutical ingredients. Building scale in this way will drive double digit sales growth and substantial margin expansion in this attractive sector beginning in 2019/20.

In New Markets, JM is focused on battery material technology and has plans to make an initial investment of up to £200 million, starting in 2018, to build capacity to drive growth in a market which could be more than $30 billion sales when battery electric vehicle penetration increases to around 10%.

Guidance is confirmed for the year ending 31st March 2018 and at constant currency with sales growth expected to be c6% with improving operating performance offset by non-cash items. Guidance on foreign exchange is unchanged; it is expected to benefit operating profit by £13 million with estimated restructuring benefits in this financial year unchanged at £10 million.

The group presentation will describe a further £50 million of savings, mainly from procurement, over the three years beginning in financial year 2018/19. Most of the savings will be reinvested with the balance for margin expansion. This is in addition to the £25 million of cost savings announced in June 2017.

Commenting on the capital markets day, Robert MacLeod, Chief Executive, said:

'Johnson Matthey has strong market leading businesses capable of sustained growth and value creation over the short, medium and long term.

'We will enhance our leadership in the high margin, technology driven growth markets we operate in through focused investment and efficiency throughout the group. We are world class chemists. We have the expertise to solve our customers' complex and increasingly challenging problems by scaling up fundamental chemistry to provide commercial solutions which drive our growth.

 'This will create value and a cleaner and healthier world. Through the strategy we will describe at our capital markets day today, we aim to be one of the best performing, most trusted and admired specialty chemical companies in the world.'

Ends

 

Enquiries:

 

Investor Relations

Simon McGough

Sarah Armstrong

Katharine Burrow

 

Head of Investor Relations

Head of Investor Relations

Investor Relations Analyst

 

020 7269 8235

020 7269 8426

020 7269 8444

 

Media

Sally Jones

David Allchurch/Latika Shah

 

 

Director of Corporate Communications

Tulchan Communications

 

 

020 7269 8407

020 7353 4200

www.matthey.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPGURABUPMPUU
Date   Source Headline
22nd Apr 20243:39 pmRNSHolding(s) in Company
18th Apr 20245:33 pmRNSDirector/PDMR Shareholding
17th Apr 20243:07 pmRNSHolding(s) in Company
10th Apr 20243:10 pmRNSHolding(s) in Company
10th Apr 20249:47 amRNSHolding(s) in Company
9th Apr 20249:00 amRNSHolding(s) in Company
8th Apr 20249:00 amRNSHolding(s) in Company
3rd Apr 20245:16 pmRNSHolding(s) in Company
2nd Apr 20249:01 amRNSHolding(s) in Company
2nd Apr 20249:00 amRNSHolding(s) in Company
27th Mar 20241:46 pmRNSHolding(s) in Company
22nd Mar 20243:11 pmRNSHolding(s) in Company
21st Mar 202412:13 pmRNSDirector/PDMR Shareholding
20th Mar 20247:00 amRNSJohnson Matthey sale of Medical Device Components
18th Mar 20243:05 pmRNSHolding(s) in Company
18th Mar 20242:32 pmRNSHolding(s) in Company
12th Mar 20245:12 pmRNSHolding(s) in Company
12th Mar 20249:00 amRNSHolding(s) in Company
11th Mar 20249:00 amRNSHolding(s) in Company
7th Mar 20244:20 pmRNSHolding(s) in Company
22nd Feb 20244:53 pmRNSDirector/PDMR Shareholding
20th Feb 20243:57 pmRNSHolding(s) in Company
19th Feb 20243:12 pmRNSHolding(s) in Company
15th Feb 20249:54 amRNSDirector/PDMR Shareholding
9th Feb 20244:17 pmRNSHolding(s) in Company
9th Feb 202412:31 pmRNSDirector/PDMR Shareholding
8th Feb 20242:17 pmRNSHolding(s) in Company
1st Feb 20244:08 pmRNSHolding(s) in Company
29th Jan 20243:22 pmRNSHolding(s) in Company
29th Jan 20242:37 pmRNSHolding(s) in Company
29th Jan 20242:35 pmRNSHolding(s) in Company
23rd Jan 20244:47 pmRNSHolding(s) in Company
19th Jan 20242:18 pmRNSHolding(s) in Company
18th Jan 20242:30 pmRNSHolding(s) in Company
18th Jan 202411:54 amRNSDirector/PDMR Shareholding
10th Jan 20241:29 pmRNSHolding(s) in Company
9th Jan 20241:31 pmRNSHolding(s) in Company
5th Jan 20244:50 pmRNSHolding(s) in Company
4th Jan 20244:26 pmRNSHolding(s) in Company
2nd Jan 20243:27 pmRNSHolding(s) in Company
28th Dec 20231:35 pmRNSHolding(s) in Company
21st Dec 20231:25 pmRNSDirector/PDMR Shareholding
19th Dec 20232:29 pmRNSHolding(s) in Company
15th Dec 20239:00 amRNSHolding(s) in Company
13th Dec 20233:01 pmRNSHolding(s) in Company
11th Dec 20234:20 pmRNSHolding(s) in Company
7th Dec 20231:41 pmRNSHolding(s) in Company
6th Dec 20231:52 pmRNSHolding(s) in Company
6th Dec 202312:00 pmRNSDirector/PDMR Shareholding
5th Dec 20232:56 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.